American Liver Foundation Partners with Helio Genomics to Combat Liver Cancer Through Innovative Testing

An Innovative Partnership in the Fight Against Liver Cancer

In a groundbreaking initiative, the American Liver Foundation (ALF) has announced a new collaboration with Helio Genomics, aiming to provide millions of Americans opportunity to assess their risk of liver cancer. This partnership acknowledges the rising public health crisis that liver cancer represents; it is a silent disease that often goes undiagnosed until it reaches advanced stages.

Raising Awareness of Liver Cancer

With liver cancer rates tripling since 1980 and the mortality rates doubling throughout the same period, the urgency for proactive steps in monitoring and treatment has heightened. Lorraine Stiehl, the CEO of ALF, emphasizes the goals of the partnership, stating their shared commitment to increase awareness, improve health outcomes, and initiate early diagnosis for liver cancer patients. She poignantly recalls her personal connection to the disease, as her father-in-law succumbed to liver cancer.

To kickstart awareness, ALF invites people to participate in a brief online quiz available at this link designed to help them understand their risk factors for liver cancer. Those identified as at risk will be able to utilize the newly introduced LiverTrace test, which allows users to obtain results quickly and conveniently from the comfort of their own homes.

The LiverTrace Test: A Game Changer

The LiverTrace test, developed by Helio Genomics, simplifies the process of liver cancer detection. It involves a visit from a certified phlebotomist who will collect a blood sample and send it to a CLIA-certified laboratory for analysis. Results will be available in a secure online portal within 10 to 14 days, allowing individuals a privacy-centric approach to understanding their health status. Such innovation will empower patients to collaborate with healthcare professionals promptly, should any issues arise.

According to Dr. Bharat Tewarie, CEO of Helio Genomics, their mission revolves around transforming early cancer detection through innovative technology and convenient at-home testing. The partnership signals a beacon of hope in making early liver cancer detection accessible to a wider audience, aiming to prolong the lives and improve the quality of life of those at risk. He stated, "Early detection isn’t just a matter of science—it’s about ensuring survival."

Who Should Get Tested?

Early detection is essential for individuals who may possess risk factors like a family history of cancer, liver cirrhosis, chronic hepatitis infections (like HCV or HBV), or conditions such as obesity, type 2 diabetes, and heavy alcohol use. The partnership between ALF and Helio Genomics is particularly crucial in educating these at-risk individuals about the importance of early screening and proactive health measures.

For additional information on the LiverTrace test, interested individuals can explore this resource for detailed insights. Moreover, ALF urges anyone who might be dealing with liver disease to make use of their support network, which includes a helpline available at 1-800-GO-LIVER (800-465-4837) during regular business hours.

Conclusion

The collaboration between the American Liver Foundation and Helio Genomics marks a pivotal point in enhancing public health sustainability regarding liver health. By promoting continuous engagement through education and accessible testing, they are not just facilitating early detection but also fostering a supportive community for patients and their family members in the fight against liver cancer. As this partnership takes off, it carries the promise of improved health outcomes and a deepened public understanding of liver-related issues.

For more stories and updates, visit the American Liver Foundation’s official website.